None of the 43 antibiotics in development as well as recently approved medicines are enough to combat the increasing emergence and spread of antimicrobial resistance, the World Health Organization cautioned on April 15.
AstraZeneca Plc said on April 14 that China’s health regulator expanded the use of Tagrisso, the British drugmaker’s lung cancer treatment, in patients with a type of lung cancer when diagnosed at an early stage.
The U.S. Food and Drug Administration granted accelerated approval of Gilead Sciences Inc.’s Trodelvy (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 or a programmed death-ligand 1 inhibitor.
Eli Lilly is cutting 163 jobs by closing its Dermira facility in Menlo Park, Calif. and selling off the latter company’s sweat drug Qbrexza, which is being acquired by Journey Medical.
The U.S. Food and Drug Administration approved a prefilled syringe for self-injection of the allergic diseases treatment Xolair developed by Novartis and Genentech, a Roche company.
Gilead Sciences Inc. said on April 12 that the company decided to stop a late-stage trial of the intravenous treatment Veklury in high-risk non-hospitalized patients with Covid-19.
AstraZeneca’s diabetes drug Farxiga (dapagliflozin) failed to reach endpoints in a Phase III study as a potential treatment for hospitalized Covid-19 patients at serious risk of developing complications.
Treating Covid-19 patients at home with a commonly used inhaled asthma drug called budesonide can speed up their recovery, according to UK trial results on April 12 which doctors said could change the way the disease is treated around the world.
Bristol Myers Squibb announced topline data from the Phase III CheckMate -648 trial on April 8, with positive results in esophageal cancer.
The U.S. Food and Drug Administration granted full approval to Gilead Sciences Inc.’s Trodelvy (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.